NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
Clinical Trials
10 trialsNCT05905341 2023-11-08
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn
NCT03803761 2023-09-25
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT04901299 2023-08-01
HER2-Signal
Massachusetts General Hospital
Phase 2 Withdrawn
NCT05191004 2023-07-11
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
Nuvation Bio Inc.
Phase 1/2 Withdrawn
NCT04316169 2022-12-23
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
Medical College of Wisconsin
Phase 1 Withdrawn
NCT04498520 2021-05-18
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
University of California, San Francisco
Phase 1 Withdrawn
NCT03377101 2018-08-14
Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT02140437 2015-12-29
Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC
Fudan University
Phase 2 Withdrawn
NCT02115594 2014-10-08
ENCORE305
Syndax Pharmaceuticals
Phase 2 Withdrawn